22:43:14 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.


2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2022-06-09 12:59:12

(Stockholm, 9 June 2022) Inhalation Sciences (ISAB) and RISE Research Institutes of Sweden have collaborated successfully on a first proposal to a major global project into antibiotic resistance and inhaled antibiotics. RISE is an ISAB customer and a leading player within Sweden promoting collaborative research between academia, industry and the public sector.

The research project, APRINHA, is being carried out by JPIAMR (the Joint Programming Initiative on Antimicrobial Resistance). It will explore the strong potential of inhaled antibiotics to help reduce antibiotic resistance - an urgent issue for researchers as antibiotic resistance has surged during the COVID-19 pandemic due to a dramatic increase in the use of antibiotics to treat pulmonary complications, co-infections and secondary infections.

The first proposal that ISAB and RISE submitted, as part of a wider consortium, has been invited to proceed to the next level. It received encouraging feedback from JPIAMR's scientific review panel: "The project is well-written; the consortium has all the expertise to achieve the goals of the project... one of the strengths of the project is that it has potential for other multiresistant bacteria, with approaches that can be translated for other infectious models."

The consortium must now submit a full proposal by July 5. ISAB's pre-clinical in vivo technology will play an important role. Its unique one-animal-at-a-time technology enables the individual control of inhaled doses of aerosol and delivers high-precisians results with a standard deviation of <10%.

Ian Cotgreave, Vice President of the Department for Chemical and Pharmaceutical Safety, RISE: "We have had very positive experience with PreciseInhale, our ISAB aerosol system, and we welcome the expertise in aerosol delivery and PK studies that the ISAB team will combine with ours as we move forward."

Manoush Masarrat, CEO ISAB: "This is an international project with applications from top research organizations and consortia worldwide. We are very pleased to be partnering together with RISE, an important partner in inhalation drug development, at this level."